Once again a trial testing the erythropoiesis-stimulating agent darbepoetinalfa (Aranesp, Amgen) has produced a negative result.
FORBES: Yet Another Negative Trial For Amgen's Aranesp
2.
Biotechnology giant Amgen today pleaded guilty in federal court to a misdemeanor charge of misbranding Aranesp (darbepoetin alfa), its highly successful anemia drug.
FORBES: Amgen Pleads Guilty To Misbranding Anemia Drug Aranesp
3.
However, no significant improvements in outcomes were associated with darbepoetinalfa.
FORBES: Yet Another Negative Trial For Amgen's Aranesp